Plasma p217+tau concordance with 18F‐NAV4694 beta‐amyloid and 18F‐MK6240 tau PET in mild Alzheimer’s disease and cognitively unimpaired participants in the AIBL/ADNeT cohort

Abstract

AbstractBackgroundBeta‐amyloid (Aß) PET assists diagnosis of Alzheimer’s disease (AD) and has an important role in selection for trials. Aß PET is costly. Reports suggest that plasma measures of phospho‐tau have high concordance with both Aß and tau PET. We compared a new assay, plasma p217+tau to Aß and tau PET.Method181 MCI/mild AD and 222 cognitively unimpaired (CU) participants in AIBL and the Australian Dementia Network (ADNeT) trial screening program were studied. Aß PET threshold was set at 25 centiloids (CL) as the standard for defining a positive scan and also at 50 CL which best correlates with NIA/AA AD neuropathologic change criteria. In CU we also evaluated a 20 CL PET threshold as this may be used in preclinical trial selection. Tau PET threshold was set at the SUVR (normalised to cerebellar cortex) for a meta‐temporal ROI (entorhinal cortex, amygdala, parahippocampus, and fusiform, inferior and middle temporal gyri) at the 95th percentile of Aß PET negative CU. Plasma p217+tau was measured with SIMOA using a Janssen in‐house assay. ROC area under the curve (AUC) was generated with Youden Index defined sensitivity (sens) and specificity (spec).ResultRank‐order correlation between p217+tau and Aß CL was significant in MCI/AD: ρ=0.65, p<10‐22 and CU: ρ=0.45, p<10‐12 and with tau SUVR for MCI/AD:ρ=0.68, p<10‐25 and CU:ρ=0.32, p<10‐7. In MCI/AD the AUC for p217+tau to predict Aß >25CL was 0.91 (sens 83%, spec 85%) and at >50CL was 0.90 (sens 73%, spec 93%). For tau+ PET the AUC was 0.86 (sens 73%, spec 90%). In the CU, the AUC vs Aß >25CL was 0.84 (sens 81%, spec 81%) dropping to 0.79 (sens 72%, spec 82%) for the 20CL PET threshold. The AUC vs tau+ PET in CU was 0.87 (sens 90%, spec 76%).ConclusionPlasma p217+tau showed good concordance with PET defined Aß and tau positivity in both MCI/AD and CU indicating potential to support the diagnosis of AD and to screen for preclinical AD trials. Early triage with p217+tau may reduce the number of screening Aß PET needed to identify Aß+ PET CU for preclinical trials by 50%.